Clinsys Clinical Researchannounced the launch of Clinsys ALTERNA for customized Phase I–IV alternative solutions.
Bedminster, NJ-April 10, 2008-Clinsys Clinical Research, a therapeutically focused global contract research organization, today announced the launch of Clinsys ALTERNA, which utilizes its Global Project Solution® (Clinsys GPS®) to augment clinical resource services. The new division demonstrates Clinsys’ commitment to aligning its service offerings with its sponsors’ and the life sciences industry’s continuously evolving staffing needs.
Clinsys ALTERNA provides customized Phase I–IV clinical trial alternative solutions to the conventional outsourcing model. The division is a core element of Clinsys GPS, a unique, highly effective, and proven integrated project management solution that brings the sponsor and the Clinsys project teams together to collaborate and agree on all aspects of the clinical study-before, during, and after-to ensure the project’s success.
“Clinsys ALTERNA provides a targeted and flexible clinical resourcing model that adapts to best serve a sponsor’s trial management needs,” said David E. Williams, chief executive officer of Clinsys. “We devoted the time and energy required to approach the evolution of resourcing in an innovative way that both maximizes efficiencies and decreases deliverable timelines.”
Drawing on extensive clinical research experience, Clinsys ALTERNA delivers a custom-designed, time-sensitive clinical solution that enables sponsors to engage its services in site management, clinical monitoring, project management, drug safety, regulatory, and medical writing on a contract basis. Clinsys ALTERNA combines therapeutic expertise, clinical screening, performance reviews, site references, and global reach to offer clients the most dependable and comprehensive alternative approach to their trial needs. Visit clinsysalterna.com for more information.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.